(Total Views: 837)
Posted On: 07/04/2022 9:30:52 AM
Post# of 154003
Re: mightycydy #125926
Quote:
Scott Kelly: Regarding the NASH, about how NASH attracted partnerships, we just presented the PDFF and cT1 and biomarker data at EASL in London, just to shed some color on the importance of the EASL meeting, there were over 7,000 delegates present or online from 114 countries. There were 1,722 abstracts presented. There were only 4 poster presentations selected for a walking tour with the chairman at EASL. And We were one of those 4. I was present and I can tell you, it was well received by the scientific community. We can not comment on potential partnerships. But there are multiple opportunities for NASH and NASH HIV.
and
Quote:
Scott Kelly: I can't speak for GSK, but Haleon, as I understand it, is basically a way for GSK to separate its consumer health care business from GSK. So I believe what they are doing is looking to increase their portfolio brand. GSK has stated that it expects to deliver organic sales growth of at least 4-6% through this new venture in the medium term. So this does bring up an important point. So the entire biopharma industry is expected by wall street to have a 7.5% growth rate annually, but that growth rate is expect to drop to 2.6% by 2024. So this anticipated drop in annual growth may well create greater opportunities for companies with late stage assets as pharmaceutical companies explore more efficient paths to regulatory approvals for new drugs.
(9)
(0)
